In the first quarter of fiscal 2025, the Company expects total revenue to increase to a record $6.2 million, compared to $1.0 million the first quarter of fiscal 2024. The first quarter of fiscal 2025 includes a one-time $3.0 million payment of collaboration revenue from the expanded distribution agreement with Zimmer Biomet for commercialization of the Company’s OneRF Ablation System, which was announced in October 2024 and is expected to be fully recognized in the first quarter of fiscal 2025. As previously announced, the agreement with Zimmer will provide NeuroOne with an additional milestone payment if certain performance criteria are achieved and is expected to generate meaningful revenue and expand product margins for the Company.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NMTC:
- NeuroOne Medical announces change to virtual investor webinar
- NeuroOne Medical sees FY25 product revenue $8M-$10M vs. $3.5M last year
- NeuroOne Sees Revenue Surge Amid Strategic Partnership
- NeuroOne Medical reports FY24 EPS (46c) vs (65c) last year
- Options Volatility and Implied Earnings Moves Today, December 17, 2024